Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomastis (Chua TC, et al.)"

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 168-

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CARCINOMATOUS PERITONITIS; CLINICAL RESEARCH; CONTROL GROUP; CYTOREDUCTIVE SURGERY; DATA ANALYSIS; DRUG PENETRATION; HUMAN; HYPERTHERMIC THERAPY; LETTER; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL;

EID: 69249206507     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.024     Document Type: Letter

References (5)

1. Ozols R.F., Locker G.Y., Doroshow J.H., Grotzinger K.R., Myers C.E., and Young R.C. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39 8 (1979) 3209-3214
2. Los G., Mutsaers P.H.A., van der Vijgh W.J.F., Baldew G.S., de Graaf P.W., and McVie J.G. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49 (1989) 3380-3384
3. Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J. Clin. Oncol. 25 27 (2007) 4168-4170
4. Williams S.F., Mick R., Desser R., Golick J., Beschorner J., and Bitran J.D. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J. Clin. Oncol. 7 12 (1989) 1824-1830
5. Peters W.P., Ross M., Vredenburgh J.J., Meisenberg B., Marks L.B., Winer E., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 11 6 (1993) 1132-1143